Japan reaping the benefits from faster drug approval process

European drugmakers say that at least as far as they are concerned, Japan is beginning to reap the benefits from its drug regulator's faster process of reviewing and approving drug applications. The head of the European Federation of Pharmaceutical Industries and Associations also applauded the changes in the "innovation premium" of Japan's Pharmaceutical and Medical Devices Agency (PMDA) pricing system that makes it more attractive to sell in Japan. Chairman Carsten Brunn said in an interview with EURObiz Japan that together the changes are also a boon to Japan, where 10% of the world's top 100 drugs that have not been available to patients are now entering the local market. FiercePharmaAsia story | Subscribe

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.